亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

乌斯特基努马 医学 银屑病 银屑病面积及严重程度指数 内科学 临床终点 随机化 安慰剂 随机对照试验 意向治疗分析 胃肠病学 皮肤病科 肿瘤坏死因子α 病理 英夫利昔单抗 替代医学
作者
Craig L. Leonardi,Alexa B. Kimball,Kim Papp,Newman Yeilding,Cynthia Guzzo,Yuhua Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon
出处
期刊:The Lancet [Elsevier BV]
卷期号:371 (9625): 1665-1674 被引量:1874
标识
DOI:10.1016/s0140-6736(08)60725-4
摘要

Background Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis. Methods In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-severe psoriasis were randomly assigned to receive ustekinumab 45 mg (n=255) or 90 mg (n=256) at weeks 0 and 4 and then every 12 weeks; or placebo (n=255) at weeks 0 and 4, with subsequent crossover to ustekinumab at week 12. Patients who were initially randomised to receive ustekinumab at week 0 who achieved long-term response (at least 75% improvement in psoriasis area and severity index [PASI 75] at weeks 28 and 40) were re-randomised at week 40 to maintenance ustekinumab or withdrawal from treatment until loss of response. Both randomisations were done with a minimisation method via a centralised interactive voice response system. The primary endpoint was the proportion of patients achieving PASI 75 at week 12. Analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00267969. Findings All randomised patients were included in the efficacy analysis. 171 (67·1%) patients receiving ustekinumab 45 mg, 170 (66·4%) receiving ustekinumab 90 mg, and eight (3·1%) receiving placebo achieved PASI 75 at week 12 (difference in response rate vs placebo 63·9%, 95% CI 57·8–70·1, p<0·0001 for 45 mg and 63·3%, 57·1–69·4, p<0·0001 for 90 mg). At week 40, long-term response had been achieved by 150 patients in the 45 mg group and 172 patients in the 90 mg group. Of these, 162 patients were randomly assigned to maintenance ustekinumab and 160 to withdrawal. PASI 75 response was better maintained to at least 1 year in those receiving maintenance ustekinumab than in those withdrawn from treatment at week 40 (p<0·0001 by log-rank test). During the placebo-controlled phase, adverse events occurred in 278 (54·5%) of the 510 patients receiving ustekinumab and 123 (48·2%) of the 255 receiving placebo. Serious adverse events occurred in six (1·2%) of 510 patients receiving ustekinumab and in two (0·8%) of 255 receiving placebo in this phase. The pattern of adverse events was much the same in the placebo crossover and randomised withdrawal phases as it was in the placebo-controlled phase. Interpretation Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients. Funding Centocor Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
突突完成签到 ,获得积分10
1秒前
2秒前
3秒前
3秒前
sue发布了新的文献求助10
5秒前
6秒前
6秒前
无语的幻露完成签到,获得积分10
6秒前
初初初啊发布了新的文献求助10
8秒前
萧雨墨发布了新的文献求助10
9秒前
9秒前
千早爱音完成签到 ,获得积分10
9秒前
DTS发布了新的文献求助10
10秒前
11秒前
11秒前
抚琴祛魅完成签到 ,获得积分10
12秒前
17秒前
何在完成签到,获得积分10
18秒前
Lucas的应助被DTS采纳,获得10
19秒前
21秒前
Ziezer完成签到,获得积分10
22秒前
初初初啊发布了新的文献求助10
22秒前
生性不爱说话完成签到,获得积分10
24秒前
DTS完成签到,获得积分10
26秒前
可爱多婷婷子完成签到 ,获得积分10
26秒前
单身的曲奇完成签到,获得积分10
27秒前
霸气的远望完成签到 ,获得积分10
30秒前
30秒前
Nole的应助被pursuit采纳,获得30
31秒前
迪恩关注了科研通微信公众号
34秒前
初初初啊发布了新的文献求助10
35秒前
reece完成签到 ,获得积分10
37秒前
葡萄味的果茶完成签到 ,获得积分10
39秒前
LeoYiS214完成签到,获得积分10
40秒前
41秒前
43秒前
梨理完成签到 ,获得积分10
44秒前
秀丽战斗机关注了科研通微信公众号
45秒前
45秒前
Nole的应助被科研通管家采纳,获得10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792